Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran
Pierre Sié Hematology Laboratory, Academic Hospital of Toulouse, Hospital Rangueil, Toulouse, France Abstract: Idarucizumab is the first targeted antidote of dabigatran, a direct oral anticoagulant used for prevention and treatment of venous thromboembolism and prevention of stroke in atria...
I tiakina i:
| Kaituhi matua: | |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Dove Medical Press
2016-05-01
|
| Rangatū: | Drug Design, Development and Therapy |
| Ngā marau: | |
| Urunga tuihono: | https://www.dovepress.com/spotlight-on-idarucizumab-and-its-potential-for-the-reversal-of-antico-peer-reviewed-article-DDDT |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|